Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Heart failure (HF) is a complex condition characterized by ventricular remodeling.
• Current treatments aim to improve cardiac function and patient outcomes.
• Understanding the impact of combined therapies on HF progression is crucial.

Purpose of the Study:

• To evaluate the effects of candesartan (C), enalapril (E), and their combination (C+E) with or without metoprolol CR (M) on ventricular remodeling in patients with heart failure.
• To assess the impact of different treatment regimens on ejection fraction, cardiac volumes, and other hemodynamic parameters.

Main Methods:

• Patients with New York Heart Association class II-IV HF and ejection fraction <0.40 were randomized in the RESOLVD study.
• Initial randomization was to C, E, or C+E. A subsequent randomization assigned patients to metoprolol CR (M) or placebo.
• Cardiac volumes, ejection fraction, blood pressure, heart rate, and neurohormones were measured over 43 weeks.

Main Results:

• The combination of candesartan, enalapril, and metoprolol (C+E+M) resulted in a significant reduction in end-diastolic and end-systolic volumes (-6.4 mL and -16.5 mL, respectively).
• Ejection fraction significantly improved by +0.05 in the C+E+M group (P<0.0001).
• Heart rate decreased significantly in groups receiving metoprolol (C+M/E+M and C+E+M) compared to those without (P<0.01).

Conclusions:

• The triple combination therapy (C+E+M) demonstrated a modest but beneficial effect on cardiac function and ventricular remodeling in HF patients.
• This combination therapy holds potential for providing additional benefits to patients with heart failure.
• Further research may explore optimal combination strategies for HF management.